DEGIACOMI, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 653
EU - Europa 467
AS - Asia 160
OC - Oceania 2
SA - Sud America 2
Totale 1.284
Nazione #
US - Stati Uniti d'America 644
IE - Irlanda 241
CN - Cina 141
IT - Italia 70
FI - Finlandia 54
DE - Germania 32
UA - Ucraina 25
SE - Svezia 11
AT - Austria 9
BE - Belgio 9
CA - Canada 9
IN - India 7
SG - Singapore 7
GB - Regno Unito 6
FR - Francia 3
RU - Federazione Russa 3
AU - Australia 2
CZ - Repubblica Ceca 2
TR - Turchia 2
BR - Brasile 1
CL - Cile 1
GR - Grecia 1
HK - Hong Kong 1
MY - Malesia 1
PK - Pakistan 1
RO - Romania 1
Totale 1.284
Città #
Dublin 241
Chandler 185
Ashburn 63
Helsinki 41
Jacksonville 36
Pavia 33
Lawrence 30
Medford 30
Princeton 30
Shanghai 29
Beijing 25
Nanjing 24
Wilmington 17
New York 16
Boardman 12
Nanchang 12
Ann Arbor 8
Changsha 8
Hangzhou 8
Los Angeles 8
Piscataway 8
Shenyang 8
Vienna 8
Jiaxing 7
San Genesio ed Uniti 7
Brussels 6
Cinisello Balsamo 6
Hebei 6
Ottawa 6
Singapore 6
Washington 5
Milan 4
Tianjin 4
Woodbridge 4
Achel 3
Dearborn 3
Fiorano Modenese 3
Pune 3
Toronto 3
Chicago 2
Fairfield 2
Falkenstein 2
Frankfurt am Main 2
Hyderabad 2
Kunming 2
Marcallo Con Casone 2
Melbourne 2
Olomouc 2
San Francisco 2
San Martino in Strada 2
Seattle 2
Shimla 2
Taizhou 2
Verona 2
West Jordan 2
Auburn Hills 1
Baoding 1
Buffalo 1
Corteolona 1
Focsani 1
Fuzhou 1
Gunzenhausen 1
Handan 1
Houston 1
Islamabad 1
La Canada Flintridge 1
Legnano 1
Lodi 1
London 1
Manassas 1
Phoenix 1
Pioltello 1
Reading 1
Redwood City 1
Rockville 1
Taiyuan 1
Tappahannock 1
Voghera 1
Totale 1.011
Nome #
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis 84
Biological and structural characterization of theMycobacterium smegmatis nitroreductase NfnB, and its rolein benzothiazinone resistance 81
Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals are Uniformly Susceptible to Benzothiazinones 74
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG. 71
Decaprenylphosphoryl-beta-D-ribose 2’-epimerase from Mycobacterium tuberculosis is a magic drug target. 67
A phenotypic based target screening approach delivers new antitubercular CTP synthetase inhibitors 66
Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis. 61
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK 61
In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. 45
New insights into the mechanism of action of the thienopyrimidine antitubercular prodrug TP053 42
Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug 42
Nitric oxide-releasing compounds for the treatment of lung infections 38
Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity 38
A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis 38
Mycobacterium abscessus, an Emerging and Worrisome Pathogen among Cystic Fibrosis Patients. 37
Pyridine-2-thiol 1-oxide derivatives and their use for treatment of mammalian infections caused by Mycobacterium or fungi 36
Functional investigation of the antitubercular drug target Decaprenylphosphoryl-β-D-ribofuranose-2-epimerase DprE1/DprE2 complex 36
First triclosan-based macrocyclic inhibitors of InhA enzyme 32
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme 31
P146 New weapons are necessary to fight Mycobacterium abscessus 30
Age-related changes in PD-1 expression coincide with increased cytotoxic potential in Vδ2 T cells during infancy 28
A New Benzothiazolthiazolidine Derivative, 11726172, Is Active In Vitro, In Vivo, and against Nonreplicating Cells of Mycobacterium tuberculosis 27
Design of Anti-infectious Agents from Lawsone in a Three-Component Reaction with Aldehydes and Isocyanides 26
Promoter mutagenesis for fine-tuning expression of essential genes in Mycobacterium tuberculosis 26
GarA is an essential regulator of metabolism in mycobacterium tuberculosis 24
The antimalarial mefloquine shows activity against mycobacterium abscessus, inhibiting mycolic acid metabolism 24
Micrococcin P1 – A bactericidal thiopeptide active against Mycobacterium tuberculosis 22
The antibacterial prodrug activator Rv2466c is a mycothiol-dependent reductase in the oxidative stress response of Mycobacterium tuberculosis 21
Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression 21
Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options 18
Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatization 17
New Drugs and Novel Cellular Targets against Tuberculosis 17
Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3 17
Whole cell screen based identification of spiropiperidines with potent antitubercular properties 17
CanB, a Druggable Cellular Target in Mycobacterium tuberculosis 16
PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis 14
The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo 14
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium 9
Concomitant assessment of PD-1 and CD56 expression identifies subsets of resting cord blood Vδ2 T cells with disparate cytotoxic potential 9
null 3
Distinct Effects of Moxifloxacin and Bedaquiline on Growing and 'Non-Culturable' Mycobacterium abscessus 3
Exploring the plasticity of the InhA substrate-binding site using new diaryl ether inhibitors 1
Totale 1.384
Categoria #
all - tutte 6.590
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.590


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020166 33 44 3 5 6 6 5 22 3 22 16 1
2020/202192 9 5 1 7 10 7 4 25 6 7 9 2
2021/2022141 5 1 1 0 2 2 5 14 8 5 14 84
2022/2023598 47 54 7 33 42 59 1 34 293 7 10 11
2023/2024301 50 52 8 16 18 54 12 28 5 15 26 17
2024/20259 9 0 0 0 0 0 0 0 0 0 0 0
Totale 1.384